IFNB1 and myeloid sarcoma: Analysis was also performed in the MS subgroup (n = 29) to compare differential methylation of those patients treated with dimethyl fumarate (n = 12) versus all other individuals with MS (n = 17, 8 on glatiramer acetate, 6 on ocrelizumab, 1 on beta-interferon, and 1 untreated).